Skip to main content
Lavipharm S.A. logo

Lavipharm S.A. — Investor Relations & Filings

Ticker · LAVI ISIN · GRS246003008 LEI · 213800USC69CRPRGWJ15 AT Manufacturing
Filings indexed 42 across all filing types
Latest filing 2025-04-14 Regulatory Filings
Country GR Greece
Listing AT LAVI

About Lavipharm S.A.

https://lavipharm.com/

Lavipharm S.A. is an integrated healthcare company engaged in the research, development, manufacturing, marketing, and distribution of pharmaceutical products. Established in 1911, the company offers a diverse portfolio that includes prescription (Rx) and over-the-counter (OTC) medicines, as well as food supplements. A key area of innovation for the company is its development of transdermal drug delivery systems. Lavipharm focuses on providing treatment options across several major therapeutic areas, including cardiology, neurology (Central Nervous System), urology, oncology, and chronic pain management.

Recent filings

Filing Released Lang Actions
ΔΕΛΤΙΟ ΤΥΠΟΥ
Regulatory Filings Classification · 95% confidence The document is a press release dated 14.04.2025, written in Greek, announcing a strategic joint venture between Lavipharm and Tikun Olam Europe to establish a company for providing telemedicine services, specifically focusing on pain management and pharmaceutical cannabis products. This announcement details a significant business development, partnership, and strategic move, but it is not a formal regulatory filing like a 10-K, an earnings release (ER), or a dividend notice (DIV). It is a general corporate announcement regarding a new business operation/partnership. Given the options, this type of strategic business update, which is not explicitly covered by other specific codes (like M&A, Financing, or Director changes), fits best under the general 'Regulatory Filings' (RNS) category as a significant corporate event announcement, or potentially 'Capital/Financing Update' (CAP) if the joint venture formation implies a major capital structure change, but RNS is a safer general announcement category when the core event is a new business line/partnership. Since it is a specific announcement of a new business venture, and not a standard periodic report, RNS is the most appropriate fallback for a significant, non-standard corporate action announcement.
2025-04-14 Greek (modern)
Οικονομική Έκθεση LAVIPHARM Α.Ε. (2024,Ετήσιος Ισολογισμός,Μητρική-Ενοποιημένη)-iXBRL
Annual Report (ESEF) Classification · 100% confidence FY 2024
2025-04-03 Greek (modern)
Financial Report LAVIPHARM S.A. (2024,Year Statement,Both)-iXBRL
Annual Report (ESEF) Classification · 100% confidence FY 2024
2025-04-03 English
Οικονομική Έκθεση LAVIPHARM Α.Ε. (2023,Ετήσιος Ισολογισμός,Μητρική-Ενοποιημένη)-iXBRL.zip
Annual Report (ESEF) Classification · 100% confidence FY 2023
2024-03-21 Greek (modern)
Οικονομική Έκθεση LAVIPHARM Α.Ε. (2022,Ετήσιος Ισολογισμός,Μητρική-Ενοποιημένη)-iXBRL.zip
Annual Report (ESEF) Classification · 100% confidence FY 2022
2023-03-27 Greek (modern)
Οικονομική Έκθεση LAVIPHARM Α.Ε. (2021,Ετήσιος Ισολογισμός,Μητρική-Ενοποιημένη)-iXBRL.zip
Annual Report (ESEF) Classification · 100% confidence FY 2021
2022-03-21 Greek (modern)

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.